2026-8-25 (Tue)

Business NVIDIA Corporation (NASDAQ: NVDA) is a leading designer of graphics processing units (GPUs) and accelerated-computing platforms, dominant in AI training/inference infrastructure. Its data-center and AI products power the global artificial-intelligence buildout.

Today’s take NVDA fell 2.91% (-$6.25) to $208.48 on Aug 24, extending a seven-session losing streak (cumulative -7.5%), its longest since Sept 2022 and >10% below the May 14 record close of $235.74. A convergence of negatives drove the slide days before Q2 earnings (Aug 26). Markets were rattled by reports NVDA told top customers AI-server prices (Vera Rubin, Grace Blackwell racks) would rise >15% due to surging HBM/DRAM memory costs (Vera Rubin storage cost up ~435% to ~$2M per Morgan Stanley), fueling margin and demand-elasticity fears. The Philadelphia Semiconductor Index fell 2.7% (Micron -5.83%) on the session. Taiwan prosecutors indicted nine people, including an Nvidia employee and two Super Micro staff, for smuggling 74 AI servers containing NVDA chips to China, raising export-control compliance risk. A 30-year Treasury yield above 5.3% pressured high-multiple growth stocks, while scrutiny grew over NVDA's circular-financing model (US$500B third-party compute platform, equity stakes in OpenAI/Anthropic and a US$105B lease backstop). Wall Street expects ~$92B revenue (+97% YoY) and EPS $2.09, with options pricing a potential ~$300B swing, prompting pre-earnings de-risking.

Business Intel Corporation designs, develops, manufactures, markets, and sells computing and related products worldwide (United States, Ireland, Israel, and internationally). One of the world's largest semiconductor companies and a dominant supplier of microprocessors and chipsets, its segments include Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. Products cover client/commercial CPUs, discrete GPUs, edge and connectivity solutions, data-center/AI chips, and foundry/manufacturing services.

Today’s take Intel fell 3.12% to $87.26 on the Monday, Aug 24, 2026 US session (reported in Asian media on Aug 25), weighed by the lingering supply/dilution overhang from its $20B secondary stock offering plus a broad semiconductor selloff. Per SEC filings, Intel priced 210,526,315 shares at $95, representing roughly 4-5% dilution. With shares trading ~9% below that $95 offering price and below both the 20-day SMA (8.4% below) and 50-day SMA (18.7% below), investors trimmed exposure. On Aug 12, BofA's Vivek Arya reiterated Buy but cut his price target from $160 to $145, citing 4-5% EPS dilution. The Nasdaq fell 0.75%, the S&P 500 0.20%, and the Technology sector dropped 1.5%, compounding the chip-name decline. Intel's 52-week gain is still ~253% with beta of 2.24.

Business Plug Power, a hydrogen fuel-cell and electrolyzer maker, saw its shares slide 4.41% to $2.17 on elevated volume, driven by a lack of fresh company-specific catalysts after a BlackRock/Russell-driven rally, rising Treasury yields repricing rate-sensitive hydrogen names, and lingering balance-sheet concerns following the DOE's termination of its $1.66B loan guarantee and the abandonment of its 100MW Antwerp green-hydrogen project with a €13.6M write-off.

Today’s take The target session decline of 4.41% to $2.17 came as a 'sell-the-news' unwind after a brief rally fueled by BlackRock increasing its stake 21% to ~13% ownership and Russell Investments boosting its position 553.9%. On the same day competitor Bloom Energy advanced on AI-driven data-center demand (partly boosted by a Pelosi trade), drawing inflows toward names better positioned for the AI power theme while hydrogen-only names like PLUG lacked fresh catalysts. Compounding the move, 10-year US Treasury yields crept back toward 52-week highs, mechanically repricing long-horizon, cash-consuming businesses via higher discount rates and financing costs. Sentiment was further pressured by the DOE terminating its $1.66B loan guarantee after the drawdown deadline lapsed, and the Antwerp project cancellation with a €13.6M write-off, which revived structural liquidity/balance-sheet fears even as Q2 operations improved (revenue +9% Q/Q, EPS beat of -$0.07, FY26 growth guidance raised to 15-16%). Analyst views diverged widely, with BMO Capital reaffirming 'Underperform' on liquidity risk while Roth Capital (PT $5) and HC Wainwright (PT $7) remained constructive.

Business BitMine Immersion Technologies, Inc. (NYSE: BMNR) is a U.S.-based blockchain infrastructure company operating institutional ETH staking/validation (via its MAVAN platform), bitcoin mining, and strategic digital asset management. It is the world's largest corporate Ethereum treasury, having accumulated ~5.85 million ETH (~4.8% of circulating supply).

Today’s take BMNR closed at $24.14, +5.74%, on 66.16M shares, extending a multi-day surge driven by the company's Aug 23-24 disclosure that its crypto+cash+marketable securities+"moonshot" holdings reached $14.9B, including 5,847,611 ETH (4.8% of supply) after buying 32,447 ETH in a week. Chairman Tom Lee was the key voice: he highlighted ETH's 30% weekly gain (largest since May 2025/July 2021, both of which preceded subsequent gains of +167% and +170%), projected $330M annualized staking revenue, and appeared on the Aug 25 Bankless podcast laying out a 10-year vision for Ethereum as the tokenization/AI blockain. Fundstrat's Lee had also named BMNR (80% ETH correlation), MSTR, and COIN top crypto picks. A ~31.8% seven-day ETH rally revalued the treasury and drove the stock ~1.3x higher from its July low, with the stock clearing the 200-day EMA. Volume was ~1.77x its ~37.4M average, confirming genuine accumulation rather than drift.

Business MARA Holdings (MARA) is a Nasdaq-listed bitcoin miner that pivoted into AI/high-performance-computing infrastructure. The market action on the session matching this dataset (Aug 24, 2026) centered on Bitcoin finally reclaiming $80,000 for the first time since mid-May, after days of crypto regulatory optimism around the U.S. Clarity Act. Yet unlike peers that surged on the BTC breakout, MARA closed essentially flat-to-down (-0.71% to $11.18), consolidating after a roughly +22% one-week run-up that peaked with a +15.5% surge on Aug 20. The stock gave back early gains into the close on elevated volume as leaders rotated out of the high-beta miner ahead of the next session's +5.81% breakout to $11.83. Important note: the provided close/change/volume figures (11.18 / -0.71% / 61.3M) match the A

Today’s take Data Reconciliation: The supplied figures (close 11.18, change -0.71%, volume 61.32M) exactly match the Aug 24, 2026 session (stockanalysis.com: close 11.18, -0.71%, volume 61,067,424; 10jqka: 11.180 -0.080, NASDAQ Aug 24 4:00PM EDT, open 11.17, high 12.06, low 11.03). The Aug 25 session actually posted close 11.83, +5.81%, volume 48.2M. The dataset therefore describes Aug 24, and that is the session analyzed. Context & catalyst: MARA is the largest pure-play bitcoin miner (holds ~35,577 BTC). The primary drivers of the broader move are (1) Bitcoin breaking $80,000 for the first time since mid-May and (2) renewed political support for the Clarity Act (crypto regulatory clarity), which lifted the whole crypto complex; MARA had already rallied +22% over the prior week, +15.5% on Aug 20 alone. On Aug 24 the global move showed crypto miners lifting (Riot +7%, MARA +7% intraday per headlines), but MARA's print closed -0.71% on a wide ~9% intraday band (11.03-12.06) - classic consolidation/profit-taking after the parabolic run, as the stock faded from early gains into the close. The next session (Aug 25) the BTC breakout fully priced in with +5.81%. Underlying fundamentals remain weak: Q

Business UiPath, Inc. (NYSE: PATH) is a leading enterprise software company in business orchestration and automation, with a platform where AI agents reason, robots act, and people lead. The company integrates automation, orchestration, AI, and testing into governed, scalable workflows for the world's most regulated industries, and is listed on the New York Stock Exchange.

Today’s take The catalyst was UiPath's announcement (published Aug 24, 16:00 ET; Released Aug 25, 2026) that it will host an Investor Day on September 22, 2026 in Las Vegas. Note a data-labeling discrepancy: the provided snapshot (Close 16.57, +1.10%, vol ~59.95M) maps to the Aug 24 NYSE session per StockAnalysis (Open 16.28, High 16.72, Low 16.20, Close 16.57, +1.10%, vol 59,639,248), while the Aug 25 session closed at 16.66 (+0.54%, vol 70,096,850). The +1.10% move reflects a modest gain amid an extraordinary recent rally — PATH surged from ~$10 in late June to ~$16.66, roughly +60%+, driven by its debut profitable quarter, rising agentic-AI adoption, the WorkFusion acquisition, and new product launches (Maestro Case, Coding Agents). Q2 FY earnings are expected Sept 3, 2026, adding forward-looking momentum. The Investor Day announcement and pre-earnings optimism, not a single binary event, anchored the session's upside.

Business Space Exploration Technologies Corp. (NASDAQ: SPCX) designs, manufactures and launches reusable rockets and spacecraft, operating Falcon 9 and Falcon Heavy for commercial, civil, international and government missions, and provides high-speed, low-latency satellite broadband through its Starlink low-earth-orbit constellation.

Today’s take SPCX fell 1.44% to close at $135.00 on Monday, August 25, 2026, exactly at its IPO price, driven by a confluence of negative catalysts. The dominant story was Elon Musk's weekend outline on X of a plan to eventually retire Falcon 9 and Falcon Heavy, shifting engineering resources to Starship — an existential operational risk since Falcon 9 is the workhorse (140-145 flights planned in 2026 vs 165 last year) and the company's primary revenue engine. Adding to the overhang, DZ Bank (analyst Markus Leistner) on August 20-21 initiated coverage with a Sell rating and a $100 price target, implying ~25.4% downside from ~$134, warning of 'excessive investment'. The second post-IPO lockup tranche expired August 20, releasing ~319M shares (about 88% of the 13B float unlocks through 2027; Musk's 6.42B shares stay locked to June 2027). The stock had already broken below $135 intraday on Thursday (closing $132.69, -5%), ending six straight closes above the benchmark, so Monday's session was an 'IPO-price defense' test. A Trump financial disclosure dated August 25 showed his portfolio bought $15,001-$50,000 of SPCX post-IPO and was down ~13.5%, sharpening government-ties scrutiny.

Business American Airlines Group Inc. (NASDAQ: AAL) is the world's largest airline by passenger count, headquartered in Fort Worth, Texas. The company operates an extensive domestic and international route network, and management has recently pivoted toward expanding premium seating and upgrading in-flight amenities to boost profitability.

Today’s take On the Aug 24, 2026 US trading session (user-labeled 2026-08-25), AAL fell 1.37% to close at $13.63 with volume of ~53.6M shares. The primary same-day catalyst was TD Cowen cutting American Airlines' price target from $24 to $16 (maintaining a Buy rating), part of a broad airline-sector target reduction also covering Alaska Air ($59→$46), Southwest ($53→$48), Delta ($112→$105), and United ($205→$192). The -$8 target cut (~33%) reflects a softer outlook amid shifting yield/pricing dynamics. Context: AAL had already declined ~2% on Aug 18 despite announcing a premium-seat and seatback-screen strategy, and Wells Fargo maintained a Hold with a $17 target on Aug 19. The stock sits near multi-month lows, with the target cut reinforcing bearish sentiment in the session.

Business Ford Motor Company (NYSE: F) is one of the world's largest automakers, designing, manufacturing, and marketing cars, trucks, SUVs, and commercial vehicles under the Ford and Lincoln brands. Its flagship F-Series Super Duty pickups and Ford Pro commercial/fleet unit are key high-margin franchises. Ford operates through Ford Blue (gas/hybrid), Ford Model e (EVs), and Ford Pro, with heavy North American manufacturing integration across the USMCA supply chain including plants in Canada and Mexico.

Today’s take Ford fell 3.33% to $13.93 on the session as President Trump, in an Aug 24 Truth Social post threatening all Canadian cars, trucks, parts, and steel tariffs of 50% effective Jan 1, 2027, after US-Canada trade talks collapsed. Investing.com flagged Ford as 'arguably the most vulnerable large automaker to a Canada tariff shock' given its ~$5B retooling of the Oakville, Ontario plant to build Super Duty pickups. CNBC confirmed Ford and Stellantis both closed down over 3% while GM slid over 1% on the tariff headlines. A secondary overhang: NHTSA opened an Aug 25 probe into intermittent brake loss on 82,040 units of the 2024 Ford Maverick Hybrid, part of broader scrutiny of 1.2M+ GM/Ford vehicles. The move was fundamentally-driven sector-wide de-rating rather than a momentum event; Q2 2026 EPS of $0.42 beat, yet the company still posted a $1.3B net loss with negative margins.

Business NIO Inc. (formerly NextEV Inc.) is a Shanghai, China-headquartered designer, developer, and manufacturer of premium and mass-market smart electric vehicles (EVs). Listed on the NYSE (ADR: NIO) and Hong Kong Stock Exchange (09866.HK), it operates a multi-brand strategy spanning NIO (premium), ONVO, and firefly sub-brands, along with battery-swap, battery-as-a-service (BaaS), and Power Home charging infrastructure.

Today’s take NIO fell -5.83% to $4.36 (close) on 2026-08-25 on a China EV 'sector-sentiment' selloff, not a company-specific fundamental event. The trigger was peer XPeng's Q2 2026 report: revenue of RMB19.74B missed consensus (~RMB20.5B), with soft Q3 guidance ~15% below estimates; XPeng's ADR dropped ~7-8.5% and its HK shares crashed 9.19%, dragging the broader China EV complex (NIO, Li Auto, Leapmotor) into risk-off. Secondary pressures: NIO broke and closed below the critical $4.45 support to a fresh 52-week low of $4.34 (range 4.34-8.02), roughly 45% off its high, accelerating technical selling ahead of NIO's own Q2 earnings due Sept 1. Fresh 13F filings showed heavy institutional trimming (D.E. Shaw -52.5%, JPMorgan -59%, Deutsche Bank -17.9%), while Morgan Stanley added 86.2% to become top holder. July deliveries were 35,934 (+71% YoY but down from June's 40,597). During the session, reports surfaced that smart-driving chief Ren Shaoqing founded an embodied-AI unicorn ($1B) startup in which NIO will make a strategic investment, though this sentiment-positive headline failed to offset the sector-wide pressure.

Business Expion Energy, Inc. (formerly Expion360 Inc., Nasdaq: XPON), headquartered in Redmond, Oregon, is a leader in premium lithium iron phosphate (LiFePO4) batteries for recreational vehicles, marine, light EV and industrial applications. The company recently expanded into oil and gas exploration in Eastern Louisiana after rebranding to align with its broadened energy platform.

Today’s take On Aug 24, 2026 (reported as Aug 25 in Asia-Pac timestamps), XPON surged +80.49% to $6.20 on a cluster of transformative corporate announcements. (1) The company acquired the Eastern Louisiana Oil and Gas Exploration Prospect for $3.425M in cash — including ~3,000 net acres of leasehold, a wellbore, and 13,000 net acres of mineral title research — marking its first entry into oil & gas, targeting AI data-center power demand and Gulf Coast LNG. (2) It closed an initial $9.0M private placement of 8% convertible debentures plus warrants for up to 2,117,219 shares at $4.25, netting ~$8.2M with an optional additional $91.0M. (3) The corporate name changed from Expion360 Inc. to Expion Energy, Inc. (effective Aug 20, 2026), and (4) Kevin Sellers was appointed CEO effective Aug 24, replacing Joseph Hammer. With only ~962,335 shares outstanding after a 1-for-12 reverse split (Nasdaq re-listing compliance regained Aug 4, 2026), the micro-float amplified the move amid heavy speculative and short-covering activity.

Business Sadot Group Inc. (NASDAQ:SDOT) is a global agri-food and commodity supply chain company headquartered in Burleson, Texas. It sources and trades agri-commodities such as soybean meal, wheat and corn, operates farms in Southern Africa, and is transitioning to an AI-powered commodity trading platform built on its TradeOS and TradeIQ systems.

Today’s take On the Aug 24, 2026 session SDOT surged ~75.7% to close at $23.16, extending an extreme low-float rally after an SEC filing confirmed elimination of the company's remaining February debentures. Sadot retired the final ~$543,478 principal by issuing 67,936 shares at $8 each on Aug 21, clearing all ~$1.08M of the original February debenture obligations via equity swaps (earlier Aug 17 and Aug 19 settlements retired $271,739 each). This debt cleanup added to momentum already driven by the AI pivot — the TradeOS platform processed its first commercial transactions in July generating ~$1M preliminary gross revenue, and Q2 2026 net income surged to $35.2M (EPS $109.16) largely on a deconsolidation gain, while revenue fell to zero. A 1-for-20 reverse split in late May sharply reduced the float, amplifying the percentage move, and Nasdaq compliance was conditionally regained in early August. Intraday the stock hit ~$25-$27 before settling; the move reflects speculative/short-covering dynamics around restructuring headlines, constrained float, and dilution risk from ongoing equity issuances.

Business Picard Medical, Inc. (NYSE American: PMI) is a medical device company that, through its SynCardia subsidiary, markets the SynCardia Total Artificial Heart - the only total artificial heart with full FDA and Health Canada approval - as a temporary bridge for patients awaiting heart transplant. The company is also developing the Emperor, a next-generation fully implantable total artificial heart platform.

Today’s take PMI surged 59.81% to close at $5.13 on the target session after Q2 FY2026 earnings (reported after the close on Aug 19) crushed expectations. Revenue rose 39% to ~$3.0M vs consensus of just $1.55M, gross profit swung to ~$0.6M (20.9% margin vs -6.0% a year earlier), and net loss narrowed 16% to ~$5.7M, driven by higher US SynCardia Total Artificial Heart sales. Volume exploded to 21.27M shares (vs ~60K normal). The momentum continued: after-hours added ~9-12%, and on Aug 25 the stock surged another 86.16% to $9.55 on 40.88M shares (intraday high $11.13), triggering an NYSE American volatility trading halt. A 1-for-50 reverse split effective July 31 and NYSE American compliance plan acceptance also supported the narrative. Despite the move, fundamentals remain fragile with only $38K cash against ~$7.45M liabilities.

Business Future Vision II Acquisition Corp. is a Cayman Islands-based special purpose acquisition company (SPAC) listed on NASDAQ under ticker FVN, formed with the goal of completing a business combination. In January 2026 it signed a merger agreement (at ~$90M enterprise value) to combine with MicroTouch Technology Inc., a deal approved by shareholders on July 28, 2026.

Today’s take The +52.62% surge to $19.84 took place during the August 24, 2026 US session (labeled 08-25 in Asia timezone reporting), not on any new fundamental announcement. Volume surged to 291,401 shares versus a typical ~40-50K average, with the stock opening at $12.90, spiking to an intraday high of $21.88 (a fresh 52-week high), and triggering multiple NASDAQ volatility trading halts (halted ~13:45 EDT, resumed ~13:55 EDT). The spike was a speculative, low-float short-squeeze style run ahead of the pending MicroTouch deSPAC merger, driven by converging catalysts: the July 28 shareholder approval (with $41.2M redeemed from trust, leaving trust value ~$10.97/share), the Aug 21 vote to extend the merger deadline to September 2026 (with possible monthly extensions to Sept 2027), and an Aug 13 $191,500 convertible sponsor promissory note funding the extension. A prominently flagged ~62% short interest and a company disclosure that its public rights cannot be used to satisfy Reg SHO short-locate/delivery requirements amplified squeeze dynamics. Bulls bid the stock well above trust value (~$19.84 vs ~$10.97), and the move quickly unwound: the next session (Aug 25) crashed -52.47% to $9.43, confi

Business TJGC Group Limited (Nasdaq: TJGC) is a Hong Kong-based investment holding company operating through its subsidiary Ctrl Media Limited, which provides integrated marketing and advertising services in Hong Kong. The company primarily serves mobile game developers, running campaigns across digital media, social platforms, KOLs/celebrities, and offline events. It was formerly known as Ctrl Group Limited before renaming to TJGC Group Limited in November 2025.

Today’s take TJGC surged +30.90% to close at $6.10 on the August 24, 2026 session (open 4.62, high 6.39, low 4.61) on heavy volume of ~4.92M shares, versus an average of roughly 700K. The run-up stems from the August 10 announcement that TJGC is negotiating a non-exclusive, worldwide AI & robotics technology IP license for its intelligent automation strategy, driving a weekly move from ~$4.01 (Aug 17) to $6.10 (+52%). The stock is an extremely speculative micro-cap (market cap ~$61.6M, 10.1M shares, ~$47-66M range) marked by violent daily swings (e.g., -23.1% on Aug 5, -11.2% on Aug 6). Note: the research tab labels the session close as 08-25, but per stockanalysis.com/Yahoo the +30.9%/$6.10 move occurred on the Aug 24 session; Aug 25 closed at $6.56 (+7.54%). A Rosen Law Firm investigation was announced Aug 18 over alleged misleading disclosures, adding to volatility risk.

Business Gogoro Inc. (Nasdaq: GGR) is a Cayman-incorporated, Taipei-headquartered global technology leader in battery-swapping electric mobility. It designs and sells smart electric scooters and operates the Gogoro Network 'GoStation' battery-swapping network, serving nearly 700,000 riders across over 2,700 stations, with revenue split between battery-swapping subscriptions and hardware sales in Taiwan, India, and internationally.

Today’s take The +29.07% surge closing at $2.93 (volume ~1,458,821) was the earnings reaction to Gogoro's Q2 2026 results released August 24, 2026, before the open (the flag date of 2026-08-25 in the data feed corresponds to the Aug 24 session; on the following session, Aug 25, the stock gave back ~8.5% to $2.68). Q2 revenue returned to growth at $70.6M (+7.3% YoY, +10.0% constant currency), the first YoY growth in quarters. Both IFRS and non-IFRS gross margin hit 22.6%, the highest in more than five years (vs 0.3% year ago), driven by a $10.9M cut in battery-upgrade costs after the program's Q4 2025 completion. Net loss narrowed by $21.6M to $4.9M (from $26.5M), adjusted EBITDA rose to $19.3M, and H1 operating cash flow reached $26.0M (+71.5% YoY) — the fifth straight positive quarter. Taiwan market share rebounded to 6% from 2%, Gogoro-branded scooter registrations grew 50.8% YoY, and subscribers reached 677,000. The company reaffirmed 2026 revenue guidance of $285M-$305M.

Business InterCure Ltd. (d/b/a Canndoc) is an Israeli pharmaceutical-grade medical cannabis producer dual-listed on Nasdaq (INCR) and the Tel Aviv Stock Exchange (TASE). Vertically integrated seed-to-sale, it is Israel's largest licensed cannabis producer and a GMP-certified supplier of dried inflorescences and cannabis extracts, also expanding into the German medical cannabis market.

Today’s take On August 24, 2026, InterCure finalized a NIS 230 million (~US$77 million) settlement with the Israeli Tax Authorities and Compensation Fund for indirect damages from the October 7, 2023 attacks — the definitive catalyst for the +28.71% one-day surge to $5.48. The claim had originally exceeded NIS 300 million (~$100M), with NIS 101 million (~$34M) already received in advance, so the settlement delivers substantial one-time liquidity to a ~$69M market-cap company. Management will deploy the funds to accelerate rehabilitation of Canndoc's flagship Nir Oz cultivation facility (destroyed on Oct 7 and inoperable since) and support German medical cannabis expansion. Compounding the move, the company's 1-for-5 reverse share split took effect at the same Aug 24 open (approved Aug 11, 2026 EGM) to regain Nasdaq $1.00 bid compliance, mechanically re-basing the price and amplifying the percentage gain. CEO Alexander Rabinovitch framed the settlement as shifting the company 'from recovery back to growth.' Note: the Aug 25 session actually closed at $5.77 (+5.29%); the +28.71% move occurred on the Aug 24 session.

Business SuperX AI Technology Limited (NASDAQ: SUPX) is a Singapore-incorporated full-stack artificial intelligence infrastructure solutions provider serving AI data centers with proprietary hardware, advanced software, and end-to-end services including high-performance AI servers, 800VDC power solutions, high-density liquid cooling, AI cloud, and AI agents. The company IPO'd on NASDAQ on April 17, 2024.

Today’s take SUPX surged +23.71% to close at $10.54 on the session matching August 24, 2026 historical data, driven by the disclosure that its Japanese subsidiary SuperX Industries secured a US$38.8 million commercial purchase order from WOODMAN Inc. to supply NVIDIA B300 GPU-based server clusters for an AI infrastructure project in Yokohama, Japan. This marks the company's first commercial collaboration with WOODMAN and a key milestone in expanding into Japan's high-performance AI compute market. Delivery is planned for mid-November 2026, with approximately 20% advance payment (~$7.76M) already received as of August 20, 2026. The news was supplemented by the company's earlier August 6 announcement of a new US$20 million share repurchase program following completion of its prior $20M buyback. Volume on the surge session reached ~1,430,019 shares, roughly 4x recent average daily volume, confirming heavy catalyst-driven buying.

Business AIFU Inc. (Nasdaq: AIFU), formerly Fanhua Inc./AIX Inc., is a China-based AI-driven independent financial services and insurance distribution platform, providing life, health, and property insurance products through licensed agency operations and digital service platforms. Founded in 1998 and headquartered in Shenzhen, it targets mass-affluent and high-net-worth clients. In June 2026 it signed an MOU to acquire industrial AI company Peakleap Ventures.

Today’s take AIFU closed at $22.20, up +20.00% (+$3.70), in the US Monday session that Chinese media cited under Beijing time Aug 25 — making it the 5th-biggest gainer among Chinese ADRs that day (finet/jrj). The move had no specific fundamentals dated to the session; it reflects extreme volatility and short-squeeze dynamics in a low-float (~6.18M shares), microcap Chinese ADR. After crashing ~52% (Aug 17, with a volatility trading halt) to a $11.30 low (Aug 19), the stock staged a sharp multi-session rebound, peaking intraday at $27.54 before closing at $22.20. Supporting context: a 1-for-20 reverse split (June 16, 2026), an F-3 registration statement for a securities offering (May 26, 2026), a new CFO (Form 3, Aug 25), and a non-binding MOU to acquire industrial AI firm Peakleap Ventures (June 2026). Volume that session was ~92K vs ~40.5K average, confirming active speculative trading.

Business Alvotech S.A. (NASDAQ: ALVO) is a Luxembourg-based, Iceland-founded biopharmaceutical company specializing in the development and manufacture of biosimilar medicines for autoimmune, eye, bone, respiratory, and oncology indications. It has five biosimilars approved and marketed globally, with a pipeline of 13 disclosed biosimilar candidates. Alvotech partners with Teva for U.S. commercialization.

Today’s take ALVO surged +18.51% to close at $5.25 (from $4.43) on Monday, August 24, 2026, extending a five-day winning streak, after BofA Securities initiated coverage with a Buy rating and $7.00 price target (~58% upside). BofA framed the thesis around Alvotech entering its 'most significant launch cycle since its founding,' with the investment debate shifting from regulatory risk to commercial execution. The direct trigger was the FDA's formal closure (July 2026) of the Reykjavik manufacturing facility inspection with a Voluntary Action Indicated (VAI) classification, removing a key regulatory overhang. This cleared the path for Alvotech's resubmitted U.S. BLAs (June 2026) for AVT05 (Simponi biosimilar) and AVT06 (Eylea biosimilar), plus AVT16 (Entyvio biosimilar) submission. Trading volume surged to ~3.17M shares on Aug 24 (vs ~0.9M typical), confirming institutional interest driving the move.

Business First Breach, Inc. (FBDT) is a Hagerstown, Maryland-based, vertically integrated manufacturer of ammunition and ammunition components (centerfire cartridges, bullets, casings, cups) serving commercial, law enforcement, and military markets. It trades on the Nasdaq Capital Market and completed a direct listing (no underwriters) on August 20, 2026.

Today’s take FBDT's -48.62% drop to $2.05 on the session was the continued liquidation of its initial direct-listing pop. The stock debuted Aug 20, 2026, opening at $12.00 before collapsing to a $4.15 day-one close (-65.42% from open) and has since been in a multi-day freefall, with the 52-week range now $1.26-$12.00. As an ununderwritten direct listing with no lock-up, there was no price support, and shares originally sold to investors at $1-$8 had a massive speculative spike that rapidly unwound. Company fundamentals are weak (FY2025 revenue just ~$384K, down 50.4% YoY; net income negative; only 14 employees). The Aug 25 announcement of the first drone prototype flight and the Hellbender manufacturing agreement did nothing to stem the selling. Notably, the move was part of a broad de-risking of newly-listed small-cap defense/robotics names that same session (T3 Defense -46.58%, AMC Robotics -25.69%), with FBDT ranking as the #2 biggest decliner on the Nasdaq.

Business T3 Defense Inc. (NASDAQ: DFNS), formerly Nukkleus Inc., is a global aerospace & defense federated holding company that acquires and operates mission-critical defense businesses in the United States and Israel, including suppliers of generators for Iron Dome launchers, GPS-denied navigation, 3D mapping/surveillance, UAVs, and AI-based defense training platforms.

Today’s take DFNS collapsed -46.58% to $11.01 in the session around Aug 24, 2026 (the data feed labels it 2026-08-25) after the company quietly filed its Q2 2026 Form 10-Q without a press release or conference call. Revenue of $4.0M missed Noble Capital's $4.5M projection, while net loss from continuing operations came in at $85.7M and loss per share was -$182.80 (adjusted for the July 2026 1-for-125 reverse split). The bottom line was crushed by a non-cash fair-value loss of ~$80.9M on the Common Warrant liability tied to the $10M February 2026 private placement. Separately, on Aug 20, 2026 T3 disclosed a Nasdaq notice of non-compliance with the minimum $10M stockholders' equity requirement, as equity had fallen to negative $19.7M by June 30. The slide extended an unwind after an extreme speculative run-up (from ~$4.35 in late July to a ~$91 spike post-split), driving the shares down about -52% for the week. Noble Capital did raise its price target to $30 with a Buy rating on the same 10-Q, but the headline loss figures and delisting overhang dominated.

Business Republic Power Group Limited is a Singapore-based provider of customized enterprise resource planning (ERP) software solutions, consulting and technical support services, and peripheral hardware to corporate clients and government agencies in Singapore and Malaysia. Its Class A shares trade on Nasdaq under ticker RPGL.

Today’s take RPGL plunged 26.96% to $1.68 on the Aug 24, 2026 session, gapping from a $2.49 open and hitting a $1.44 low before closing at the session low on ~1.18M shares—roughly 15-20x the typical ~50-80K daily volume. Two dilution-related catalysts converged. First, at the Extraordinary General Meeting held that same day, shareholders approved a wholesale capital-structure overhaul: expanding authorized shares to 11 billion (10B Class A + 1B Class B), boosting Class B voting power from 30 to 100 votes per share, adopting the Fifth M&A charter, authorizing a board-discretionary reverse split (1-for-2 to 1-for-50) within 180 days, and approving BVI-to-Cayman redomiciliation. The massive authorized-share expansion was widely read as enabling relentless future dilution. Second, the Aug 20 F-1 registered up to 4,568,000 Class A shares (~28% of ~16.1M outstanding) for resale by selling shareholder Dune Equity Holdings, deriving from a July 24 convertible note plus commitment shares—a heavy supply overhang. The market sold off sharply on dilution fears and governance complexity. Notably, the next session rebounded +18.15% to $1.99, confirming a sharp-but-shallow panic in this low-liquidity microcap

Business AMC Robotics Corporation (NASDAQ: AMCI) is an AI-driven robotics company developing intelligent hardware and software solutions, including its quadruped robotic platform Kyro for automated inspection/security and the NovaArm warehouse logistics sorting robot. The company operates primarily across the United States, Canada, and Europe.

Today’s take On the US Monday Aug 24 session (Aug 25 Beijing time), AMCI plunged 25.69% to close at $4.83 (change -1.67), effectively unwinding the prior Friday's +32.65% surge to ~$6.50. The volatility traces to the Aug 21 warrant inducement announcement under which two investors agreed to exercise December 2025 warrants at a reduced $1.65 exercise price (vs. prior $4.017) for $1M immediate gross proceeds, with up to a further ~$1.1M within 30 trading days; AMCI will issue up to 1,219,816 new warrants at $5.775 (25% premium). This created a ~1.22M-share dilution overhang that, combined with profit-taking after the spike, triggered the sharp selloff. Q2 2026 results (Aug 17) also showed revenue fell to $937,177 from $1.40M YoY, though gross margin improved to ~80%.

Business REGENXBIO Inc. is a clinical-stage biotechnology company traded on NASDAQ, focused on developing gene therapies using its proprietary NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its pipeline targets rare genetic diseases, including Hunter syndrome (MPS II), Duchenne muscular dystrophy, and retinal diseases, with several programs partnered with AbbVie and NS Pharma.

Today’s take REGENXBIO shares plunged ~25% to $8.06 after the FDA placed a clinical hold on RGX-121, its investigational one-time gene therapy for Hunter syndrome (MPS II). The hold was triggered by asymptomatic spine MRI findings — small nodules or cystic masses detected in five CAMPSIITE trial participants who received RGX-121 three to six years earlier. The company stated it does not intend to resubmit the RGX-121 BLA in the near term, marking a major setback after a previous clinical hold on RGX-111 in January 2026 was lifted in April. This is the company's second safety-related hold in eight months. Despite the disappointment, BofA maintained a Buy rating with a $15 price target, noting it had already given the program minimal value in its model. Other catalysts include a planned RGX-202 Duchenne BLA submission this quarter and topline pivotal data for wet AMD candidate ABBV-RGX-314 in Q4. RGNX has lost ~43% year-to-date.

Business Yunji Inc. (NASDAQ: YJ) is a Chinese social e-commerce platform operator focused on membership-based online retail, marketing consumer products through a network of social shopping guides. The company's sponsored American Depositary Receipts trade on the Nasdaq as a micro-cap ADR.

Today’s take Yunji closed at $2.86 on the Aug 24, 2026 US session, down 20.78% (vol 511,114), the top decliner among Chinese ADRs. The fall is the unwind of an extreme speculative penny-stock pump: YJ spiked ~172% on Aug 19 ahead of H1 2026 earnings (released Aug 20) on ~128M shares vs a ~6,300-share 3-month average, after earlier spikes on Aug 5 (~triple) and Aug 7 hitting a 52-week high of $13.97. Fundamentals offered no support: H1 revenue fell 39.18% YoY to $14.19M (RMB96.3M from RMB158.3M), GAAP EPS was -$0.01, gross margin compressed from 47.3% to 41.0%, and net loss narrowed to RMB72.4M. The drop of ~20.78% on the session reflects momentum reversal / post-earnings unwinding of the short-squeeze-style runup in a ~$13M-market-cap ADR.

Business AIAI Holdings Corporation (NASDAQ: AIAI) is an AI-enabled diversified holding company that acquires and grows companies across multiple industries, applying exclusively licensed Transformational AI (TAI) to enhance portfolio operational efficiency and financial performance. The company, formerly MXLII Corporation, began trading May 14, 2026 via direct listing.

Today’s take On August 24, 2026, AIAI announced it was commencing discussions with Messier 42 LLC, a company controlled by founder and controlling stockholder John P. Rochon, to acquire a number of M42's existing and targeted businesses across defense, intelligence, healthcare, gaming, and rare earth minerals. The company stated these related-party transactions would be structured to be minimally dilutive. Investors reacted negatively to the news, driving the stock down 19.79% to close at $5.31, making AIAI the 10th-largest decliner on the U.S. market that session (reported globally Aug 25 Beijing time). The move extended a broader post-direct-listing decline: the stock, which debuted at around $15, had lost roughly 63% over the trailing three months. Concerns centered on the related-party nature of the deal, potential dilution even if 'minimally' dilutive, and the company's unprofitable growth phase. Yahoo history shows the Aug 24 session traded from 6.36 to close at 5.31 with elevated volume of ~907,200.

Business PS International Group Ltd. is a Cayman Islands holding company listed on the Nasdaq Capital Market (ticker PSIG). It provides air and ocean freight forwarding as well as supply chain ancillary services through its Hong Kong operating subsidiaries, Profit Sail Int'l Express (H.K.) Limited and Business Great Global Supply Chain Limited.

Today’s take PSIG fell 19.35% to close at $2.25 on the Monday US session (reported Beijing early Aug 25) after a frenzy of speculative trading. The stock had rocketed from roughly $1.08 (Aug 17) to a halt-triggered $2.79 (Aug 21) following the Aug 12 Nasdaq MVLS deficiency notice (market value below $35M, 180-day cure to Feb 8 2027), a failed Aug 18 EGM without quorum, and a new F-3 shelf declared effective Aug 19. With no fresh company-specific news on the day, the -19.35% drop was a volatility flush / profit-taking unwind of the crowded speculative position in this micro-cap Chinese ADR facing potential delisting. The prior-day 774,871-share turnover and LUDP halt on Aug 21 signal a hot, retail-driven market.

Business iPower Inc. (NASDAQ: IPW) is a Rancho Cucamonga, California-based online retailer and technology/data-driven supply chain provider for consumer home, pet, garden, outdoor, and electronics products, also pivoting toward AI infrastructure. The company has undergone two reverse stock splits in 2026 (1-for-8 in May, 1-for-9 in August) to maintain Nasdaq listing compliance.

Today’s take IPW plunged 18.48% on the August 24, 2026 session (close $2.25, down from $2.76), capping a collapse from ~$19 in late June to $2.25 — an ~88% decline in two months. The primary catalyst is severe dilutive overhang: on August 18, 2026 the company filed an S-1/A registering up to 5,873,610 shares underlying $3.15M of Series A convertible notes for resale by an institutional investor. With only ~73,500 shares outstanding post the 1-for-9 reverse split (Aug 7), this registration represents up to ~80x the current share count. The notes carry a floor price of $0.628 (20% of Aug 14 price), ensuring massive dilution upon conversion. Reuters/source data confirm the stock declined for 5 straight sessions (-28% cumulative) as the market absorbed the resale registration, which was compounded by a proxy filing on Aug 19 and the company's collapsing fundamentals (Q3 FY2026 revenue down from $16M to $3.5M YoY, GAAP loss of $3.5M). The company's market cap is now just ~$158K, nearing effective delisting. The 1-for-9 reverse split had failed to stop the bleeding, and the stock is trading near its 52-week low of $2.15.

Business Addex Therapeutics Ltd (SIX and Nasdaq: ADXN) is a clinical-stage Swiss biopharmaceutical company developing novel small-molecule allosteric modulators of G protein-coupled receptors for neurological and psychiatric disorders. Lead pipeline programs include dipraglurant (mGlu5 NAM) for post-stroke/TBI recovery and Parkinson's levodopa-induced dyskinesia, a GABAB PAM for chronic cough, and ADX71149.

Today’s take Addex released H1/Q2 2026 results before the market open on Monday, August 24, 2026, triggering a sharp ~18% selloff to close at $4.05, followed by a further slip to $3.90 (-3.7%) the next session. The decline is driven by acute going-concern stress: the company ended Q1 2026 with only CHF 0.9M in cash versus a CHF 1.7M quarterly net loss, and auditors flagged material uncertainty about its ability to continue operations. Market capitalization fell to roughly $3.8M. Despite pipeline progress on dipraglurant (Phase 1 post-stroke/TBI), the GABAB PAM chronic cough candidate, and the Neurosterix spin-out (NTX-253), the company cannot fund unpartnered programs without fresh capital, and no financing accompanied the earnings release.